No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Antibiotic Treatment for 7 is Noninferior to 14 Days in Patients with Bloodstream Infections

byAstrid BradshawandAlisha Yi

December 2, 2024

in StudyGraphics

Reading Time: 1 min read

Click here to read this study in NEJM.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Shorter antibiotic courses non-inferior for inpatient community-acquired pneumonia

Nuzolvence (Zoliflodacin) first oral Gonorrhea treatment shows non-inferior cure rates

2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate (ADC) safety concerns with ifinatamab deruxtecan (I‑DXd) [January 2026]

#VisualAbstract: Middle Meningeal Artery Embolization was Non-Inferior to Usual Care for Nonacute Subdural Hematoma

RelatedReports

Prescription of antibiotics for acute respiratory infections increasing

Infectious Disease

Shorter antibiotic courses non-inferior for inpatient community-acquired pneumonia

April 13, 2026

USPSTF recommends routinely screening asymptomatic women for chlamydia and gonorrhea

Infectious Disease

Nuzolvence (Zoliflodacin) first oral Gonorrhea treatment shows non-inferior cure rates

January 14, 2026

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Cardiology

2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate (ADC) safety concerns with ifinatamab deruxtecan (I‑DXd) [January 2026]

January 26, 2026

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization

Infectious Disease

Oral gepotidacin is non-inferior to standard therapy for uncomplicated urogenital gonorrhea

May 28, 2025

Racial differences in colorectal cancer survival linked to health at initial diagnosis

Nivolumab plus Ipilimumab in MSI-High Metastatic Colorectal Cancer

Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients

Molecular-guided therapy improves survival in unfavorable cancer of unknown primary

Axonal injury may occur up to 9 years prior to symptom onset in multiple sclerosis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result